{"disease":{"id":"vaso-occlusive-crisis-in-sickle-cell-disease","name":"Vaso-occlusive crisis in sickle cell disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"crizanlizumab","indication_name":"Vaso-occlusive crisis in sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selg1","generic_name":"CRIZANLIZUMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"P-selectin","drug_class":"Selectin Blocker [EPC]","quality_score":48,"revenue":null,"mechanism":"Selg1 works by binding to P-selectin, preventing it from interacting with its ligands."},{"drug_id":"crizanlizumab-tmca","indication_name":"Vaso-occlusive crisis in sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ADAKVEO","generic_name":"CRIZANLIZUMAB-TMCA","company_name":"NOVARTIS PHARMS CORP","drug_phase":"marketed","molecular_target":"P-selectin","drug_class":"Selectin Blocker [EPC]","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05348915","title":"A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":242,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04927247","title":"A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":72,"lead_sponsor_name":"Pfizer","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}